Online First

September 01, 2020

Correspondence
Correspondence on ‘Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case–control study’ by Potere et al
Free

Leo Buckley

doi: 10.1136/annrheumdis-2020-218693
Correspondence response
Response to: ‘Correspondence on ‘Interleukin-6 blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case–control study’ by Potere et al’ by Buckley
Free

Nicola Potere, Marcello Di Nisio, Donatella Cibelli, Rosa Scurti, Antonella Frattari, Ettore Porreca, Antonio Abbate, Giustino Parruti

doi: 10.1136/annrheumdis-2020-218715
Correspondence
Impact of lockdown on rheumatology outpatient care in the age of COVID-19
Free

Benjamin Sachdev Manjit Singh, Seow Lin Chuah, Yaw Kiet Cheong, Sharifah Aishah Wan, Cheng Lay Teh

doi: 10.1136/annrheumdis-2020-218484
Correspondence response
Response to: ‘Comment on: ‘EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update’ by Gossec et al’ by Wei et al
Free

Laure Gossec, Xenofon Baraliakos, Iain McInnes, Andreas Kerschbaumer, Maarten de Wit, Maxime Dougados, Jette Primdahl, Désirée van der Heijde, Josef S Smolen

doi: 10.1136/annrheumdis-2020-218456
Correspondence
Comment on: ‘EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update’ by Gossec et al
Free

Chen-Yu Wei, Yung-Heng Lee, James Cheng Chung Wei

doi: 10.1136/annrheumdis-2020-218385

August 31, 2020

Correspondence
Analysis on misdiagnosis of a case of novel variant of NLRP12
Free

Xiran Yang, Bo Zhao, Yabin Liao

doi: 10.1136/annrheumdis-2020-218422

August 28, 2020

Correspondence
Comment on ‘Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19’ by Konig et al. Long-term exposure to hydroxychloroquine or chloroquine and the risk of hospitalisation with COVID-19: a nationwide, observational cohort study in 54 873 exposed individuals and 155 689 matched unexposed individuals in France
Free

Emilie Sbidian, Laetitia Penso, Philippe Herlemont, Jérémie Botton, Bérangère Baricault, Laura Semenzato, Jérome Drouin, Alain Weill, Rosemay Dray-Spira, Mahmoud Zureik

doi: 10.1136/annrheumdis-2020-218647
Correspondence
Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine’ by Mathian et al
Free

Quirin Notz, Patrick Meybohm, Peter Kranke, Dirk Weismann, Christopher Lotz, Marc Schmalzing

doi: 10.1136/annrheumdis-2020-218778
Correspondence
Correspondence on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials – a real-world district general hospital experience
Free

Asim Khan, Alice Cole, Naveen Bhadauria, Munzir El-Hassan, Daud Abdulla, Thomas Axon, Zozik Fattah, Jessica J Manson, Jeronimo Moreno-Cuesta, Dev Mukerjee

doi: 10.1136/annrheumdis-2020-218528
Correspondence
Systemic lupus erythematosus and COVID-19: what we know so far
Free

Giuseppe A. Ramirez, Luca Moroni, Emanuel Della-Torre, Maria Gerosa, Lorenzo Beretta, Enrica P. Bozzolo, Lorenzo Dagna

doi: 10.1136/annrheumdis-2020-218601

August 27, 2020

Correspondence response
Anti-inflammatory action of colchicine in hospitalised patients with COVID-19. Response to: ‘Colchicine treatment in community healthcare setting to prevent severe COVID-19’ by Della-Torre et al
Free

Silvia Piantoni, Enrico Colombo, Roberto Furloni, Laura Andreoli, Antonio Brucato, Massimo Imazio, Paolo Airó, Mirko Scarsi

doi: 10.1136/annrheumdis-2020-218806
Correspondence
Colchicine treatment in community healthcare setting to prevent severe COVID-19
Free

Emanuel Della-Torre, Giuseppe A Ramirez, Lorenzo Dagna, Moreno Tresoldi

doi: 10.1136/annrheumdis-2020-218759

August 21, 2020

Correspondence
Case of postpartum axial spondyloarthritis
Free

Kazunori Furuhashi, Nanase Honda, Yuji Miyoshi, Naoto Yokogawa

doi: 10.1136/annrheumdis-2020-218587
Correspondence response
Response to: ‘Case of postpartum axial spondyloarthritis’ by Furuhashi et al
Free

Adel Hoballah, Cédric Lukas, Christophe Leplat, Patrice Taourel, Jean-Baptiste Pialat, Nicolas Sans, Sonia Ramos-Pascual, Mo Saffarini, Catherine Cyteval

doi: 10.1136/annrheumdis-2020-218687
Correspondence response
Response to: ‘Exaggerated neutrophil extracellular trap formation in Kawasaki disease: a key phenomenon behind the outbreak in western countries?’ by Yamashita et al
Free

Marie Pouletty, Glory Dingulu, Naim Ouldali, Olivier Corseri, Camille Ducrocq, Ulrich Meinzer, Albert Faye, Caroline Galeotti, Isabelle Melki Great Paris Region (GPR) Kawa-COVID-19 consortium

doi: 10.1136/annrheumdis-2020-218644
Correspondence
High risk of systemic lupus erythematosus development in patients with ITP: antiphospholipid syndrome is also a concern
Free

Murat İnanç, Bahar Artim-Esen, Reyhan Diz-Küçükkaya

doi: 10.1136/annrheumdis-2020-218345
Correspondence
Exaggerated neutrophil extracellular trap formation in Kawasaki disease: a key phenomenon behind the outbreak in western countries?
Free

Kouhei Yamashita, Akifumi Takaori-Kondo, Kiyomi Mizugishi

doi: 10.1136/annrheumdis-2020-218593

August 19, 2020

Correspondence
Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis
Free

Mendel E Singer, David C Kaelber, Maria J Antonelli

doi: 10.1136/annrheumdis-2020-218500
Correspondence
Correspondence to: ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al
Free

Rachael Mary Flood, Richard Conway, Colm Kirby, Diana Gheta, David J Kane, Ronan H Mullan

doi: 10.1136/annrheumdis-2020-218733
Correspondence response
Response to: ‘High dosage of Methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to Tocilizumab’ by Conticini et al
Free

Sofia Ramiro, Rémy Mostard, Robert BM Landewé

doi: 10.1136/annrheumdis-2020-218788
Correspondence
Challenge of diagnosing ANCA-associated vasculitis during COVID-19 pandemic: a missed ‘window of opportunity’
Free

Alessandro Giollo, Riccardo Bixio, Davide Gatti, Ombretta Viapiana, Luca Idolazzi, Christian Dejaco, Maurizio Rossini

doi: 10.1136/annrheumdis-2020-218830
Correspondence
High dosage of methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to tocilizumab
Free

Edoardo Conticini, Federico Franchi, David Bennett, Serafina Valente, Maria A Mazzei, Elena Bargagli, Luca Volterrani, Sabino Scolletta, Bruno Frediani

doi: 10.1136/annrheumdis-2020-218761
Correspondence
Correspondence on: ‘Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation—an open-label cohort study’ by Della-Torre et al
Free

Chao Cheng, Fangjie Zhang

doi: 10.1136/annrheumdis-2020-218616
Correspondence response
Impact of sarilumab on mechanical ventilation in patients with COVID-19. Response to: ‘Correspondence on: ‘Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation–an open-label cohort study’ by Della-Torre et al’ by Cheng and Zhang
Free

Emanuel Della-Torre, Giovanni Landoni, Alberto Zangrillo, Lorenzo Dagna

doi: 10.1136/annrheumdis-2020-218724

August 14, 2020

Correspondence response
Response to: ‘Tapering antirheumatic drugs in a resource-poor setting: real-world evidence’ by Haroon et al
Free

Elise van Mulligen, Pascal H P de Jong

doi: 10.1136/annrheumdis-2020-218731
Correspondence
Tapering antirheumatic drugs in a resource-poor setting: real-world evidence
Free

Muhammad Haroon, Zara Khan, Maryam Aamer

doi: 10.1136/annrheumdis-2020-218703

August 13, 2020

Correspondence
Implications of SARS-CoV-2 infection for patients with rheumatic disease
Free

Changsong Lin, Ziyu Wang, Jie Li, Xinyi Xia, Yun Liu, Qianghu Wang

doi: 10.1136/annrheumdis-2020-218050

August 12, 2020

Correspondence response
COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: ‘Correspondence on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials – a real-world district general hospital experience’ by Khan et al, ‘Comment on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry’ by Gianfrancesco M et al’ by Andreica et al and ‘COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs’ by Ansarin et al
Free

Milena Gianfrancesco, Kimme L Hyrich, Jinoos Yazdany, Pedro M Machado, Philip C Robinson

doi: 10.1136/annrheumdis-2020-218713

August 11, 2020

Correspondence
Impact of COVID-19 pandemic on hospitalisation of patients with systemic lupus erythematosus (SLE): report from a tertiary hospital during the peak of the pandemic
Free

Seow Lin Chuah, Cheng Lay Teh, Sharifah Aishah Wan Mohd Akbar, Yaw Kiet Cheong, Benjamin Sachdev Manjit Singh

doi: 10.1136/annrheumdis-2020-218475
Correspondence
Glucosamine and mortality: a note of caution
Free

Richard Conway

doi: 10.1136/annrheumdis-2020-218489
Correspondence response
Response to: ‘Glucosamine and mortality: a note of caution’ by Conway
Free

Zhi-Hao Li, Qing-Mei Huang, Wen-Fang Zhong, Xi-Ru Zhang, Chen Mao

doi: 10.1136/annrheumdis-2020-218660

August 07, 2020

Correspondence
No increased rate of SARS-CoV-2 infection for patients with inflammatory rheumatic diseases compared with the general population in the city of Hamburg (Germany)
Free

Peer Aries, Christof Iking-Konert

doi: 10.1136/annrheumdis-2020-218400
Correspondence
Correspondence on ‘Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist’ by Graef et al
Free

Chien Hsien Lo, Yu-Hsun Wang, Chin Feng Tsai, Kuei Chuan Chan, Li Ching Li, Tse Hsien Lo, Chun Hung Su, James Cheng-Chung Wei

doi: 10.1136/annrheumdis-2020-218589
Correspondence
Elucidation of disease mechanisms underlying rheumatic immune-related adverse events may lead to novel therapeutic strategies for autoimmune diseases
Free

Ryu Watanabe, Motomu Hashimoto

doi: 10.1136/annrheumdis-2020-217995
Correspondence response
Response to: ‘Correspondence on ‘Festina lente: hydroxychloroquine, COVID-19and the role of the rheumatologist’ by Graef et al’ by Lo et al
Free

Ali Duarte-García, Elizabeth R Graef, Jean W Liew, Maximilian F Konig, Alfred Hyoungju Kim, Jeffrey A Sparks

doi: 10.1136/annrheumdis-2020-218680

August 05, 2020

Correspondence response
Response to: ‘Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis’ by Singer et al
Free

Manuel Francisco Ugarte-Gil, Maximilian F Konig, Peter Korsten, Francis Berenbaum, Alfred Hyoungju Kim, Jeffrey A Sparks

doi: 10.1136/annrheumdis-2020-218683
Correspondence
COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs
Free

Khalil Ansarin, Ali Taghizadieh, Saeid Safiri, Aida Malek Mahdavi, Shirin Ranjbar, Soheil Teymouri, Masoud Ahangari Maleki, Alireza Khabbazi

doi: 10.1136/annrheumdis-2020-218737
Correspondence
Diagnostic value of ultrasound halo count and Halo Score in giant cell arteritis: a retrospective study from routine care
Free

Juan Molina Collada, Julia Martínez-Barrio, Belén Serrano-Benavente, Isabel Castrejón, Liz Rocío Caballero Motta, Laura Trives Folguera, José María Álvaro-Gracia

doi: 10.1136/annrheumdis-2020-218631
Correspondence response
Response to: ‘Diagnostic value of ultrasound halo count and Halo Score in giant cell arteritis: a retrospective study from routine care’ by Molina Collada et al
Free

Kornelis SM van der Geest, Bhaskar Dasgupta

doi: 10.1136/annrheumdis-2020-218654
Correspondence response
Response to: ‘Correspondence on ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort’ by Pouletty et al’ by Pino et al
Free

Naim Ouldali, Marie Pouletty, Johanna Lokmer, Cherine Benzouid, Constance Beyler, Anna Deho, Ulrich Meinzer, Albert Faye, Isabelle Melki Great Paris Region (GPR) Kawa-COVID-19 consortium

doi: 10.1136/annrheumdis-2020-218614
Correspondence
Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5-positive dermatomyositis-associated rapidly progressive interstitial lung diseases: a challenge for the future
Free

Yukai Wang, Guangzhou Du, Guohong Zhang, Marco Matucci-Cerinic, Daniel E Furst

doi: 10.1136/annrheumdis-2020-218594
Correspondence
Correspondence on: ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort’ by Pouletty et al
Free

Rosa Pino, Ana Carolina Izurieta, María Ríos-Barnés, Sílvia Ricart, Mariona F De Sevilla, Laura Monfort, Cristian Launes, Iván Cano, Laura Lecina, Judith Sánchez Manubens, Juan Manuel Mosquera, Iolanda Jordan, Joan Sánchez de Toledo, Manuel Monsonís, Cristina Esteva, Carmen Muñoz-Almagro, Victòria Fumadó, Clàudia Fortuny, Juan José Garcia Garcia, Antoni Noguera-Julian, Jordi Anton On behalf of the Kids Corona Project

doi: 10.1136/annrheumdis-2020-218538
Correspondence response
Response to: ‘Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5 positive dermatomyositis associated rapidly progressive interstitial lung diseases: a challenge for the future’ by Wang et al
Free

Janine A Lamb, Spyridon Megremis, Hector Chinoy

doi: 10.1136/annrheumdis-2020-218712

August 04, 2020

Correspondence
Correspondence to ‘Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study’ by Li et al
Free

Hann-Ziong Yueh, Chih-Jung Yeh, James Cheng-Chung Wei

doi: 10.1136/annrheumdis-2020-218486
Correspondence response
Response to: ‘Correspondence to ‘Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study’ by Li et al’ by Yueh et al
Free

Zhi-Hao Li, Wen-Fang Zhong, Qing-Mei Huang, Xi-Ru Zhang, Chen Mao

doi: 10.1136/annrheumdis-2020-218659
Correspondence
Women’s journey in Mexican rheumatology. Comment on ‘Gender gap in rheumatology: speaker representation at annual conferences’ by Monga et al
Free

Iris J Colunga-Pedraza, Rosa I Arvizu-Rivera, Griselda Serna-Peña, Ana Laura De-Leon-Ibarra, Deshire Alpizar Rodriguez, Alejandra Pérez-Villar, Mayra Alejandra Reyes Soto, Dionicio Angel Galarza-Delgado

doi: 10.1136/annrheumdis-2020-218541
Correspondence response
Response to: ‘Women’s journey in Mexican rheumatology. Comment on ‘Gender gap in rheumatology: speaker representation at annual conferences’ by Monga et al’ by Colunga-Pedraza et al
Free

Kanika Monga, Jean Liew

doi: 10.1136/annrheumdis-2020-218630
Correspondence
Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al
Free

Maurizio Benucci, Luca Quartuccio, Francesca Li Gobbi, Arianna Damiani, Valentina Grossi, Maria Infantino, Mariangela Manfredi

doi: 10.1136/annrheumdis-2020-218590
Correspondence response
Response to: ‘Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial–comment on: ‘Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus’ by Chatzidionysiou et al’ by Bettiol et al
Free

Katerina Chatzidionysiou, Evangelia Samoli, Petros P Sfikakis, Maria G Tektonidou

doi: 10.1136/annrheumdis-2020-218444
Correspondence
Correspondence to ‘Gender gap in rheumatology: speaker representation at annual conferences’ by Monga and Liew—gender discrepancies at annual EULAR congresses: towards the gap narrowing
Free

Paola Conigliaro, Silvia Laura Bosello, Cristina Iannuccelli, Elisa Gremese, Francesca Romana Spinelli, Marta Vadacca, Maria Sole Chimenti

doi: 10.1136/annrheumdis-2020-218516

Log in using your username and password

Main menu

Log in using your username and password

You are here

Online First

September 01, 2020

August 31, 2020

August 28, 2020

August 27, 2020

August 21, 2020

August 19, 2020

August 14, 2020

August 13, 2020

August 12, 2020

August 11, 2020

August 07, 2020

August 05, 2020

August 04, 2020

Pages